Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

8.04
-0.1000-1.23%
Volume:3.27M
Turnover:26.43M
Market Cap:8.52B
PE:-8.13
High:8.30
Open:8.15
Low:7.91
Close:8.14
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:0.86
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-8.14
PE(LYR):-21.05

Loading ...

PDS Biotech Adds Patrick Soon-Shiong, NantBio CFO James Banaag to Board

Reuters
·
Sep 14

PDS Biotech Announces Initial Closing of up to $22.3 Million Pipe Financing and the Appointment of DR. Patrick Soon-Shiong to Its Board of Directors

THOMSON REUTERS
·
Sep 14

ImmunityBio put volume heavy and directionally bearish

TIPRANKS
·
Sep 10

Does ImmunityBio’s (IBRX) Jim Yong Kim Hire Transform Its Global Access Strategy For Immunotherapies?

Simply Wall St.
·
Aug 25

Does Adding Jim Yong Kim to Leadership Shift ImmunityBio’s Global Strategy Narrative (IBRX)?

Simply Wall St.
·
Aug 15

ImmunityBio Names Former World Bank Chief Jim Yong Kim Vice Chairman

Reuters
·
Aug 10

Immunitybio Appoints DR. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

THOMSON REUTERS
·
Aug 10

Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next

Simply Wall St.
·
Aug 08

Travere Therapeutics Q2 Product Sales Rise on Filspari Demand

Reuters
·
Aug 05

U.S. Stocks on the MOVE-Expeditors International, Waters, Wayfair

Reuters
·
Aug 05

Immunitybio Falls After Posting Q2 Loss

Reuters
·
Aug 04

Shares of Immunitybio Down 3.5% Premarket After Posting Q2 Loss

THOMSON REUTERS
·
Aug 04

Immunitybio Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Earnings Flash (IBRX) ImmunityBio Posts Q2 Net Loss $0.22 a Share, vs. FactSet Est of $0.08 Loss

MT Newswires Live
·
Aug 04

ImmunityBio Q2 Adj. EPS $(0.08) Beats $(0.09) Estimate, Sales $51.240M Beat $49.700M Estimate

Benzinga Earnings
·
Aug 04

ImmunityBio Q2 FY26 Net Loss Widens to $230.4 Million; Revenue Rises 92% YoY to $50.7 Million

Reuters
·
Aug 04

Immunitybio Q2 Revenue USD 51.24 Million VS. Ibes Estimate USD 49.7 Million

THOMSON REUTERS
·
Aug 04

Immunitybio Q2 EPS USD -0.22

THOMSON REUTERS
·
Aug 04

ImmunityBio Wins UAE Marketing Authorization for Anktiva in BCG-unresponsive Bladder Cancer

Reuters
·
Jul 30

Movement Alert|ImmunityBio, Inc. Declines 5.02% in Regular Trading, Trading at $7.675

Market Focus
·
Jul 23